Drug management of appetite;Nutrition-obésité: Traitements médicamenteux de l'appétit

Revue Medicale Suisse

Volumn 7, Issue 277, 2011, Pages 57-60

  Makoundou, Vincent ^a   Golay, Alain ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMYLIN; DEXFENFLURAMINE; FENFLURAMINE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; LEPTIN; LORCASERINE; NALTREXONE; PHENTERMINE; PRAMLINTIDE; SEROTONIN AGONIST; SIBUTRAMINE; TESOFENSINE; TOPIRAMATE; UNCLASSIFIED DRUG;

ANXIETY; APPETITE; APPETITE DISORDER; DRUG MECHANISM; DRUG SPECIFICITY; HORMONAL REGULATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; NAUSEA; NERVOUSNESS; OBESITY; PATHOPHYSIOLOGY; REVIEW; SATIETY; SIDE EFFECT;

EID: 79551616714     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Grundy SM. Multifactorial causation of obesity: Implications for prevention. Am J Cli Nutr 1998;67:563S-72.
2. Otsuka R, Tamakoshi K, Yatsuya H, et al. Eating fast leads to obesity: Findings based on self-administered questionnaires among middle-aged Japanese men and women. J Epidemiol 2006;16:117-24.
3. Pearcey SM, de Castro JM. Food intake and meal patterns of weight-stable and weight gaining persons. Am J Clin Nutr 2002;76:107-12.
4. Matsuda M, Liu Y, Mahankali S, et al. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 1999;48:1801-6.
5. Gautier JF, Chen K, Salbe AD, et al. Differential brain responses to satiation in obese and Lean men. Diabetes 2000;49:838-46.
6. Pasman WJ, Saris WH, Westerterp-Plantenga MS. Predictors of weight maintenance. Obes Res 2006;7: 43-50.
7. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increase food intake in human. J Clin Endocrinol Metab 2001;86:5992-5.
8. Adam TC, Westerterp-Plantenga MS. Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese. Br J Nutr 2005;93:845-51.
9. Hirsch J, Mackintosh RM, Aronne LJ. The effects of drugs to treat obesity on the autonomic nervous system. Obes Res 2000;8:227-33.
10. Brenman AM, Mantzoros CS. Drug insight: The role of leptin in human physiology and pathophysiologie : Emerging clinical applications in leptin deficient states. Nat Clin Pract Endocrinol Metab 2006;2:318-27.
11. Vivus. VIVUS press release: VIVUS announces positive results from two phase III studies; obese patients on Qnexa achieve average weight loss up to 14.7% and significant improvements in Co-morbidities. http://ir.vivus.com/ releasedetail.cfm?ReleaseID=407933 (accessed 7 august 2010).
12. ** Halford JCG, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010;6, 255-69.
13. Gasteyger C, Sjödin A, Meier DH, et al. Effects of tesofensine on appetite in obese subjects. Obesity 2008; 16(Suppl. 1):S138-9.
14. Smith SR, Prosser WA, Donahue DJ, et al. Lorcaserin (APD356), a selective 5-HT (2C) agonist, reduces body weight in obese men and women. Obesity 2009; 17:494-503.
15. Dunayevich E, Greenway F, Erikson J, Maier H, Kim D. Two doses of Naltrexone SR/Bupropion SR combination therapy showed significant and sustained weight loss in overweight and obese subjects - A phase 3, double-blind, placebo-controlled, 56-week Study. Obesity Review 2010; 11 (Suppl. 1):226-7.
16. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-48.
17. Mars M, de Graaf C, de Groot CP, van Rossum CT, Kok FJ. Fasting leptin and appetite responses induced by a 4-day 65%-energy-restricted diet. Int J Obes (Lond) 2006;30:122-8.
18. Roth JD, Roland BL, Cole RL, et al. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008;105:7257-62.
19. Bojanowska E. Physiology and pathophysiology of glucagons-like peptide I (GLP-1): The role of GLP-1 in the pathogenesis of diabetes mellitus,obesity and stress. Med Sci Monit 2005;11:RA271-8.
20. ** Madsbad S. Exenatide and liraglutide: Different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23:463-77.
21. Ybarra J, Bobbioni-Harsch E, Chassot G, et al. Persistent correlation of ghrelin plasma levels with body mass index both in stable weight conditions and during gastric-bypass-induced weight loss. Obes Surg 2009;19: 327-31.
22. ** Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav 2006;89:71-84.